Free Trial

Nephros (NEPH) Competitors

Nephros logo
$3.57 +0.13 (+3.78%)
Closing price 07/25/2025 03:59 PM Eastern
Extended Trading
$3.60 +0.03 (+0.84%)
As of 07/25/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NEPH vs. LNSR, ELMD, PDEX, PTHL, RCEL, LAKE, LUNG, BSGM, LUCD, and OBIO

Should you be buying Nephros stock or one of its competitors? The main competitors of Nephros include LENSAR (LNSR), Electromed (ELMD), Pro-Dex (PDEX), Pheton (PTHL), Avita Medical (RCEL), Lakeland Industries (LAKE), Pulmonx (LUNG), Biosig Technologies (BSGM), Lucid Diagnostics (LUCD), and Orchestra BioMed (OBIO). These companies are all part of the "medical equipment" industry.

Nephros vs. Its Competitors

Nephros (NASDAQ:NEPH) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

41.1% of Nephros shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 6.7% of Nephros shares are held by insiders. Comparatively, 38.5% of LENSAR shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, LENSAR had 1 more articles in the media than Nephros. MarketBeat recorded 2 mentions for LENSAR and 1 mentions for Nephros. Nephros' average media sentiment score of 1.89 beat LENSAR's score of 1.87 indicating that Nephros is being referred to more favorably in the media.

Company Overall Sentiment
Nephros Very Positive
LENSAR Very Positive

Nephros has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nephros$14.16M2.67$70K$0.0751.00
LENSAR$53.49M2.88-$31.40M-$4.85-2.69

Nephros presently has a consensus price target of $5.00, indicating a potential upside of 40.06%. LENSAR has a consensus price target of $15.00, indicating a potential upside of 14.94%. Given Nephros' stronger consensus rating and higher possible upside, equities analysts clearly believe Nephros is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nephros
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
LENSAR
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Nephros has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

Nephros has a net margin of 5.16% compared to LENSAR's net margin of -99.17%. Nephros' return on equity of 9.43% beat LENSAR's return on equity.

Company Net Margins Return on Equity Return on Assets
Nephros5.16% 9.43% 7.20%
LENSAR -99.17%-737.30%-81.69%

Summary

Nephros beats LENSAR on 12 of the 16 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NEPH vs. The Competition

MetricNephrosMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$36.47M$10.55B$5.70B$9.50B
Dividend YieldN/A2.00%4.69%4.01%
P/E Ratio51.0117.0728.1020.06
Price / Sales2.6729.18428.7189.10
Price / Cash171.9123.0336.2258.56
Price / Book4.413.698.665.87
Net Income$70K$234.77M$3.25B$258.55M
7 Day Performance-1.92%6.32%4.22%3.73%
1 Month Performance-15.80%7.94%10.51%11.75%
1 Year Performance60.45%-13.57%34.40%18.02%

Nephros Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NEPH
Nephros
3.2201 of 5 stars
$3.57
+3.8%
$5.00
+40.1%
+61.5%$36.47M$14.16M51.0130
LNSR
LENSAR
1.2718 of 5 stars
$13.32
+1.7%
$15.00
+12.6%
+143.0%$154.48M$53.49M-2.75110Positive News
ELMD
Electromed
1.2781 of 5 stars
$18.13
-0.5%
$38.00
+109.6%
+26.9%$152.04M$61.44M24.17160News Coverage
Analyst Forecast
Analyst Revision
PDEX
Pro-Dex
2.4778 of 5 stars
$46.66
+1.0%
$56.00
+20.0%
+159.1%$150.63M$64.12M16.66140
PTHL
Pheton
N/A$22.61
+1.8%
N/AN/A$146.25M$450K0.0011Positive News
Gap Up
High Trading Volume
RCEL
Avita Medical
1.341 of 5 stars
$5.21
+0.8%
$16.50
+216.7%
-43.4%$136.67M$64.25M-2.38130Positive News
LAKE
Lakeland Industries
4.7544 of 5 stars
$14.14
+0.7%
$26.00
+83.9%
-37.0%$133.59M$167.21M0.002,100News Coverage
LUNG
Pulmonx
3.5908 of 5 stars
$3.18
+1.0%
$11.53
+262.4%
-57.4%$126.81M$83.79M-2.21250News Coverage
Upcoming Earnings
BSGM
Biosig Technologies
1.9472 of 5 stars
$5.76
+24.4%
$10.00
+73.6%
+964.4%$126.37M$40K0.0050Gap Up
High Trading Volume
LUCD
Lucid Diagnostics
2.7064 of 5 stars
$1.11
-0.9%
$3.55
+219.8%
+30.6%$121.17M$4.35M-0.8370
OBIO
Orchestra BioMed
3.0897 of 5 stars
$3.16
+2.3%
$14.20
+349.4%
-59.2%$118.39M$2.64M-1.784News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:NEPH) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners